LUIS GONZAGA
PAZ-ARES RODRÍGUEZ

2025

1. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

   Journal of Thoracic Oncology

2. Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)

   Journal of Thoracic Oncology, Vol. 20, Núm. 5, pp. 614-624

3. Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study

   Future Oncology, Vol. 21, Núm. 12, pp. 1511-1523

4. Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A

   Journal of Thoracic Oncology, Vol. 20, Núm. 5, pp. 651-664

5. Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC

   JTO Clinical and Research Reports, Vol. 6, Núm. 3

6. Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431] (JTO Clinical and Research Reports (2023) 4(1), (S2666364322001552), (10.1016/j.jtocrr.2022.100431))

   JTO Clinical and Research Reports

7. Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy

   Cancer research, Vol. 85, Núm. 20, pp. 3910-3929

8. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

   Journal of Clinical Oncology, Vol. 43, Núm. 3, pp. 260-272

9. Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

   Journal of Clinical Oncology, Vol. 43, Núm. 10, pp. 1254-1265

10. Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study

    Clinical Lung Cancer

11. Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial

    ESMO Open, Vol. 10, Núm. 6

12. Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial

    Lung Cancer, Vol. 209

13. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

    The Lancet, Vol. 405, Núm. 10495, pp. 2129-2143

14. Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

    ESMO Open, Vol. 10, Núm. 10

15. Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5

    JTO Clinical and Research Reports, Vol. 6, Núm. 10

16. High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

    Nature Communications , Vol. 16, Núm. 1

17. IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer

    Future Oncology, Vol. 21, Núm. 25, pp. 3275-3282

18. Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer

    Oncology and Therapy, Vol. 13, Núm. 3, pp. 667-681

19. Impacto psicológico de la pandemia por COVID-19 y burnout en profesionales de Oncología Médica, Hemato-Oncología y Oncología Radioterápica

    Psicooncología: investigación y clínica biopsicosocial en oncología, Vol. 22, Núm. 1, pp. 11-25

20. LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy

    Journal of Thoracic Oncology, Vol. 20, Núm. 10, pp. 1489-1504